TY - JOUR
T1 - The effects of dexmedetomidine on cardiac electrophysiology in children
AU - Hammer, Gregory B.
AU - Drover, David R.
AU - Cao, Hong
AU - Jackson, Ethan
AU - Williams, Glyn D.
AU - Ramamoorthy, Chandra
AU - Van Hare, George F.
AU - Niksch, Alisa
AU - Dubin, Anne M.
PY - 2008/1
Y1 - 2008/1
N2 - BACKGROUND: Dexmedetomidine (DEX) is an α2-adrenergic agonist that is approved by the Food and Drug Administration for short-term (<24 h) sedation in adults. It is not approved for use in children. Nevertheless, the use of DEX for sedation and anesthesia in infants and children appears to be increasing. There are some concerns regarding the hemodynamic effects of the drug, including bradycardia, hypertension, and hypotension. No data regarding the effects of DEX on the cardiac conduction system are available. We therefore aimed to characterize the effects of DEX on cardiac conduction in pediatric patients. METHODS: Twelve children between the ages of 5 and 17 yr undergoing electrophysiology study and ablation of supraventricular accessory pathways had hemodynamic and cardiac electrophysiologic variables measured before and during administration of DEX (1 μg/kg IV over 10 min followed by a 10-min continuous infusion of 0.7 μg·kg·h). RESULTS: Heart rate decreased while arterial blood pressure increased significantly after DEX administration. Sinus node function was significantly affected, as evidenced by an increase in sinus cycle length and sinus node recovery time. Atrioventricular nodal function was also depressed, as evidenced by Wenckeback cycle length prolongation and prolongation of PR interval. CONCLUSION: DEX significantly depressed sinus and atrioventricular nodal function in pediatric patients. Heart rate decreased and arterial blood pressure increased during administration of DEX. The use of DEX may not be desirable during electrophysiology study and may be associated with adverse effects in patients at risk for bradycardia or atrioventricular nodal block.
AB - BACKGROUND: Dexmedetomidine (DEX) is an α2-adrenergic agonist that is approved by the Food and Drug Administration for short-term (<24 h) sedation in adults. It is not approved for use in children. Nevertheless, the use of DEX for sedation and anesthesia in infants and children appears to be increasing. There are some concerns regarding the hemodynamic effects of the drug, including bradycardia, hypertension, and hypotension. No data regarding the effects of DEX on the cardiac conduction system are available. We therefore aimed to characterize the effects of DEX on cardiac conduction in pediatric patients. METHODS: Twelve children between the ages of 5 and 17 yr undergoing electrophysiology study and ablation of supraventricular accessory pathways had hemodynamic and cardiac electrophysiologic variables measured before and during administration of DEX (1 μg/kg IV over 10 min followed by a 10-min continuous infusion of 0.7 μg·kg·h). RESULTS: Heart rate decreased while arterial blood pressure increased significantly after DEX administration. Sinus node function was significantly affected, as evidenced by an increase in sinus cycle length and sinus node recovery time. Atrioventricular nodal function was also depressed, as evidenced by Wenckeback cycle length prolongation and prolongation of PR interval. CONCLUSION: DEX significantly depressed sinus and atrioventricular nodal function in pediatric patients. Heart rate decreased and arterial blood pressure increased during administration of DEX. The use of DEX may not be desirable during electrophysiology study and may be associated with adverse effects in patients at risk for bradycardia or atrioventricular nodal block.
UR - http://www.scopus.com/inward/record.url?scp=37549071486&partnerID=8YFLogxK
U2 - 10.1213/01.ane.0000297421.92857.4e
DO - 10.1213/01.ane.0000297421.92857.4e
M3 - Article
C2 - 18165557
AN - SCOPUS:37549071486
SN - 0003-2999
VL - 106
SP - 79
EP - 83
JO - Anesthesia and analgesia
JF - Anesthesia and analgesia
IS - 1
ER -